Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HIV Platform Pseudovirus > Spike protein > PSSL-HLGB006

SARS-CoV-2 Spike (Lambda) Fluc-GFP Pseudovirus

Materials Provided
Product DescriptionSARS-CoV-2 Spike (Lambda) Fluc-GFP Pseudovirus
BackboneHIV-1
Envelope proteinSARS-CoV-2 Spike Protein (Lambda | C.37)
ReporterFirefly luciferase-GFP
Physical appearanceDark red-brown transparent liquid
Storage-70°C
TransportDry ice
ApplicationNeutralization assay
  • Application

    Pseudovirus Neutralization Assay
    a. Mix 89% DMEM medium, 10% Fetal bovine serum and 1% Penicillin-Streptomycin to prepare complete DMEM medium.  
    b. Thaw the pseudovirus at room temperature. Dilute the pseudovirus with complete DMEM medium according to your pre-test results. In general, we recommend 125-fold dilution if you use the same materials and luminescence meter as those in this protocol (e. g., 20 μL Pseudovirus + 2.48 mL complete DMEM medium).
    c. Dilute your samples with complete DMEM medium in a 96-well white flat bottom plate to reach a volume of 75 μL per well, then add 25 μL pseudovirus suspension per well to reach a final volume of 100 μL per well. Gently flap to mix well. Incubate the plate in a 5% (vol/vol) CO2, 37°C incubator for 60 min.
    d. Digest and resuspend HEK293/Human ACE2 Overexpression Stable Cells (ACROBiosystems, Cat. No. CHEK-ATP042) with complete DMEM medium. Adjust the cell density to 4 ~ 5 × 105 cells per milliliter with complete DMEM medium. Seed 100 μL the cell suspension per well into the 96-well plate. Gently flap to mix well. Incubate the plate in a 5% (vol/vol) CO2, 37°C incubator for 48 h.
    e. Prepare the detection reagent (britelite plus Reporter Gene Assay System (PerkinElmer, Cat. No. 6066761)) and balance it to room temperature.  
    f. Take out the 96-well plate and discard 100 μL medium per well. Balance the plate to room temperature for 10 min. Add 100 μL detection reagent and mix well. Incubate for 2 min at room temperature.
    g. Read the luminescence values (RLU) of the wells with a luminescence meter (PerkinElmer, Cat. No. HH34000000).

  • Background

    SARS-CoV-2 Spike (Lambda) Fluc-GFP Pseudovirus uses pseudotyped HIV-1 virus with firefly luciferase and green fluorescent protein (GFP) gene as the backbone and takes SARS-CoV-2 spike protein as its envelope protein. It can effectively infect human ACE2 overexpressing cells and can be used in determining neutralizing antibody titer, screening for inhibitors of the Spike-ACE2 interaction, studying virus invasion and COVID-19 vaccine development.
    Mutation(s) compared to wild type surface glycoprotein [severe acute respiratory syndrome coronavirus 2] (Accession # QHD43416.1): G75V, T76I, RSYLTPG246-252del, D253N, L452Q, F490S, D614G, T859N ("RSYLTPG246-252del, D253N" equals to "R246N, SYLTPGD247-253del").

  • Notice

    Basic advice
    a. Though pseudovirus particles has no pathogenicity and cannot replicate, the assays should be carried out carefully in a Biosafety Level 2 or higher-level laboratory with a biosafety cabinet.
    b. Serum samples from animals or humans should be inactivated in a water bath at 56°C for 30 min before being tested.
    c. Please avoid freezing and thawing, which would influence the titer of the pseudovirus.
    d. The product is for Research Use Only.

    For more information and advice, please check the Data Sheet of this product.

    Optional Relative Products
    HEK293/Human ACE2 Stable Cell Line (ACROBiosystems, Cat. No CHEK-ATP042)
    The stable cell line is susceptible to SARS-CoV-2 Spike Fluc-GFP Pseudovirus.
    Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (ACROBiosystems, Cat. No. S1N-M122)
    The antibody is an ideal positive control for neutralization assay of wild type and multiple kinds of mutant SARS-CoV-2 Spike pseudovirus.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $880.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message